An ALS-mutant TDP-43 Neurotoxic Peptide Adopts an Anti-parallel β-structure and Induces TDP-43 Redistribution
Overview
Molecular Biology
Authors
Affiliations
TDP-43 proteinopathies are clinically and genetically heterogeneous diseases that had been considered distinct from classical amyloid diseases. Here, we provide evidence for the structural similarity between TDP-43 peptides and other amyloid proteins. Atomic force microscopy and electron microscopy examination of peptides spanning a previously defined amyloidogenic fragment revealed a minimal core region that forms amyloid fibrils similar to the TDP-43 fibrils detected in FTLD-TDP brain tissues. An ALS-mutant A315E amyloidogenic TDP-43 peptide is capable of cross-seeding other TDP-43 peptides and an amyloid-β peptide. Sequential Nuclear Overhauser Effects and double-quantum-filtered correlation spectroscopy in nuclear magnetic resonance (NMR) analyses of the A315E-mutant TDP-43 peptide indicate that it adopts an anti-parallel β conformation. When added to cell cultures, the amyloidogenic TDP-43 peptides induce TDP-43 redistribution from the nucleus to the cytoplasm. Neuronal cultures in compartmentalized microfluidic-chambers demonstrate that the TDP-43 peptides can be taken up by axons and induce axonotoxicity and neuronal death, thus recapitulating key neuropathological features of TDP-43 proteinopathies. Importantly, a single amino acid change in the amyloidogenic TDP-43 peptide that disrupts fibril formation also eliminates neurotoxicity, supporting that amyloidogenesis is critical for TDP-43 neurotoxicity.
Tang H, Sun Y, Wang L, Ke P, Ding F J Chem Inf Model. 2024; 64(19):7590-7601.
PMID: 39342654 PMC: 11590498. DOI: 10.1021/acs.jcim.4c00943.
Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS.
Tsekrekou M, Giannakou M, Papanikolopoulou K, Skretas G Front Mol Biosci. 2024; 11:1383453.
PMID: 38855322 PMC: 11157337. DOI: 10.3389/fmolb.2024.1383453.
Mutations in human prion-like domains: pathogenic but not always amyloidogenic.
Bartolome-Nafria A, Garcia-Pardo J, Ventura S Prion. 2024; 18(1):28-39.
PMID: 38512820 PMC: 10962614. DOI: 10.1080/19336896.2024.2329186.
Suresh K, Dahal E, Badano A Cell Biosci. 2024; 14(1):26.
PMID: 38374092 PMC: 10877803. DOI: 10.1186/s13578-024-01208-6.
Molecular Mechanisms of Phase Separation and Amyloidosis of ALS/FTD-linked FUS and TDP-43.
Song J Aging Dis. 2023; 15(5):2084-2112.
PMID: 38029395 PMC: 11346406. DOI: 10.14336/AD.2023.1118.